Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Account Payables: 2015-2025

Historic Change in Account Payables for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $3.7 million.

  • Spyre Therapeutics' Change in Account Payables rose 267.79% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 138.56%. This contributed to the annual value of -$16.0 million for FY2024, which is 565.32% down from last year.
  • Spyre Therapeutics' Change in Account Payables amounted to $3.7 million in Q3 2025, which was up 16,182.61% from $23,000 recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Change in Account Payables peaked at $3.7 million during Q3 2025, and registered a low of -$6.5 million during Q1 2024.
  • Its 3-year average for Change in Account Payables is -$1.1 million, with a median of -$287,000 in 2023.
  • Per our database at Business Quant, Spyre Therapeutics' Change in Account Payables soared by 29,200.00% in 2021 and then plummeted by 1,068.08% in 2024.
  • Spyre Therapeutics' Change in Account Payables (Quarterly) stood at $1.5 million in 2021, then slumped by 340.55% to -$3.5 million in 2022, then spiked by 91.80% to -$287,000 in 2023, then tumbled by 193.73% to -$843,000 in 2024, then skyrocketed by 267.79% to $3.7 million in 2025.
  • Its Change in Account Payables was $3.7 million in Q3 2025, compared to $23,000 in Q2 2025 and $3.0 million in Q1 2025.